Valuation: Genomma Lab Internacional, S.A.B. de C.V.

Market Cap 13.22B 782M 670M 627M 574M 1.08B 74.84B 1.09B 7.41B 2.89B 37.59B 2.94B 2.87B 124B P/E 2026 *
5.3x
P/E 2027 * 6.36x
Enterprise Value 17.67B 1.05B 896M 838M 767M 1.44B 100B 1.46B 9.9B 3.86B 50.26B 3.93B 3.84B 166B EV / Sales 2026 *
0.94x
EV / Sales 2027 * 0.87x
Free-Float
68.95%
Yield 2026 *
6.15%
Yield 2027 * 9.08%
24/07 Genomma Lab Internacional, S.A.B. de C.V., Q2 2026 Earnings Call, Jul 23, 2026
23/07 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
24/04 Genomma Lab Internacional, S.A.B. de C.V., Q1 2026 Earnings Call, Apr 23, 2026
24/04 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
27/02 Genomma Lab Internacional, S.A.B. de C.V., Q4 2025 Earnings Call, Feb 26, 2026
26/02 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
10/12 Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025 CI
24/10/25 Genomma Lab Internacional, S.A.B. de C.V., Q3 2025 Earnings Call, Oct 23, 2025
22/10/25 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25/07/25 Genomma Lab Internacional, S.A.B. de C.V., Q2 2025 Earnings Call, Jul 24, 2025
23/07/25 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
24/06/25 Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025 CI
05/06/25 Genomma Lab Successfully Issued the Lab 25 and Lab 25-2 Unsecured Bonds for A Total Amount of $1.2 Billion Pesos, Which Will Be Used to Prepay Liabilities, Including the Full Early Amortization of the Lab 23 Bond CI
1 day+1.42%
1 week-1.09%
Current month-7.63%
1 month-5.90%
3 months-13.19%
6 months-22.65%
Current year-24.20%
1 week 13.25
Extreme 13.25
13.8
1 month 13.25
Extreme 13.25
14.98
Current year 13.25
Extreme 13.25
19.48
1 year 13.25
Extreme 13.25
23.2
3 years 12.39
Extreme 12.39
29.18
5 years 12.39
Extreme 12.39
29.18
10 years 11.1
Extreme 11.1
29.18
Manager TitleAgeSince
Chief Executive Officer - 12/04/2023
Director of Finance/CFO - 01/12/2015
Investor Relations Contact - 01/10/2019
Director TitleAgeSince
Chairman - 30/10/1996
Director/Board Member - 06/07/2010
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.42%-1.09%-37.34%-0.88% 782M
+0.88%+6.38%+76.86%+128.23% 1,119B
+1.07%+3.80%+51.03%+61.48% 651B
+1.20%+6.21%+26.47%+76.45% 468B
+1.02%+5.77%+43.09%+47.70% 374B
+0.85%+4.07%+23.88%+41.58% 302B
+1.26%+6.81%+1.59%+14.67% 259B
+1.88%+5.81%+48.54%+68.52% 238B
+1.59%+2.09%-15.52%-52.29% 208B
+1.87%+5.61%+25.81%+92.42% 181B
Average +1.30%+4.42%+24.44%+47.79% 380.06B
Weighted average by Cap. +1.14%+5.09%+44.29%+72.53%

Financials

2026 *2027 *
Net sales 18.72B 1.11B 949M 888M 813M 1.53B 106B 1.55B 10.49B 4.09B 53.24B 4.16B 4.07B 176B 19.19B 1.14B 973M 910M 833M 1.56B 109B 1.58B 10.75B 4.19B 54.57B 4.26B 4.17B 180B
Net income 2.19B 130M 111M 104M 95.23M 179M 12.42B 181M 1.23B 479M 6.24B 487M 477M 20.63B 2.18B 129M 110M 103M 94.49M 177M 12.32B 180M 1.22B 476M 6.19B 484M 473M 20.48B
Net Debt 4.45B 263M 226M 211M 193M 363M 25.21B 368M 2.49B 973M 12.66B 989M 968M 41.88B 3.56B 211M 180M 169M 154M 290M 20.14B 294M 1.99B 777M 10.12B 791M 773M 33.47B
Logo Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Employees
1,658
Date Price Change Volume
21/08/26 MXN 13.56 +1.42% 3,008,033
20/08/26 MXN 13.37 -0.45% 3,865,365
19/08/26 MXN 13.43 -1.18% 1,819,457
18/08/26 MXN 13.59 -0.37% 3,439,090
17/08/26 MXN 13.64 -0.51% 2,832,334
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
13.56MXN
Average target price
22.67MXN
Spread / Average Target
+67.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LAB B Stock